What drugs are being tested in NCT06935188?

Interventions in NCT06935188: Dalpicilib combined with cetuximab, cetuximab.

What condition does NCT06935188 study?

NCT06935188 studies Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

Is NCT06935188 still recruiting?

NCT06935188 is currently recruiting now. Last updated 18 July 2025.

Last reviewed 2025-07-18 · How we verify

NCT06935188

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC

Recruiting now Phase 2 Last updated 18 July 2025

What this trial tests

Phase 2 trial testing Dalpicilib combined with cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in 98 participants. Currently enrolling.

Timeline

17 April 2025

Primary endpoint
31 December 2028

31 December 2030

Quick facts

Lead sponsor	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	98
Start date	17 April 2025
Primary completion	31 December 2028
Estimated completion	31 December 2030
Sites	1 location across China

Drugs / interventions tested

Dalpicilib combined with cetuximab — full drug profile →
cetuximab (cetuximab) — full drug profile →

Conditions studied

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma — all drugs for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma →

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Who can join

Adults 18 to 75, any sex, with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single center, randomized controlled, prospective phase II clinical trial to evaluate the efficacy and safety of cetuximab combined with dalpicilib compared to cetuximab monotherapy in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma. The participants would receive cetuximab combined with dalpicilib or cetuximab monotherapy until termination criteria are met.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Drug resistance in cancer: molecular mechanisms and emerging treatment strategies.
Li J, Hu J, Yang Y, Zhang H, et al · · 2025 · cited 5× · PMID 41247642 · DOI 10.1186/s43556-025-00352-w

Verify or expand the search:

Other recruiting trials for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07088211 — Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC · Phase 2 · recruiting
NCT07090317 — Iparomlimab and Tuvonralimab in HNSCC · Phase 2 · recruiting

Other Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University trials

Trials by the same sponsor.

NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
NCT07505251 — Development and Validation of the Periodontal Map Derived From IOS and CBCT Registration for Diagnosis and Treatment Pla · not yet recruiting
NCT07466810 — Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology · NA · not yet recruiting
NCT07533695 — Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis Patients · NA · not yet recruiting
NCT07490561 — The Impact of Assisted Hatching on Pregnancy Outcomes After Vitrified-Warmed Embryo Transfer in Advanced-age Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06935188 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Last refreshed: 18 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06935188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing